Cardioxyl Pharmaceuticals Announces Late Breaker at American Heart Association Conference

Chapel Hill, NC - October 29, 2009 - Cardioxyl Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing therapies for the treatment of cardiovascular disease, today announced an oral presentation and a late-breaker poster on the company's lead product, CXL-1020, at the American Heart Association (AHA) Scientific Sessions. Cardioxyl's poster is one of only 30 late-breakers accepted this year.

Chris Kroeger, MD, President and Chief Executive Officer of Cardioxyl Pharmaceuticals, commented, "We are thrilled to have this opportunity to share our growing understanding of the significant physiological effects of CXL-1020, particularly at such a prestigious conference devoted to cardiovascular health."

American Heart Association Scientific Sessions Late-Breaking Poster Session: Vascular and Cardiac Biology

Who: Carlo G. Tocchetti, Reza Mazhari, Eiki Takimoto, Norimichi Koitabashi, Djahida Bedja, Kathleen L. Gabrielson, Miguel A. Aon, David A. Kass, Nazareno Paolocci, Cardioxyl Pharmaceuticals Title: "Nitroxyl Enhances Contractility in Failing Isolated Mouse Cardiomyocytes" When: Monday, November 16, 2009, 9:00- 11:30 AM Where: Exhibit Hall, Orange County Convention Center, Orlando, Florida Website: http://scientificsessio ram

Oral Presentation: Who: Mengjun Wang, Itamar Ilsar, Alice Jiang, Michael S Sabbah, Ramesh C Gupta, Henry Ford Hosp, Detroit, MI; T D Cowart, Reza Mazhari, Cardioxyl Pharmaceuticals, Inc., Hunt Valley, MD; Hani N Sabbah, Henry Ford Hosp, Detroit, MI Title: "Acute Intravenous Infusion of CXL- 1020, a Nitroxyl Donor, Improves Left Ventricular Function in Dogs With Advanced Heart Failure" When: Tuesday, Nov 17, 2009, 2:00 PM - 5:15 PM Where: Meeting Room W109B Website: http://scientificsessio ram

About Cardioxyl Pharmaceuticals Cardioxyl Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery and development of new classes of safe and effective therapeutic agents for the treatment of cardiovascular disease. Cardioxyl has developed industry-leading expertise in the chemistry, biology and clinical applications of nitroxyl (HNO) technology. The company's core HNO platform has generated several preclinical and clinical candidates, including the company's lead compound, CXL-1020, currently in clinical development for ADHF. Cardioxyl is a privately held company financed by life science venture investors, including the Aurora Funds and New Enterprise Associates.

Contact: Lisa Rivero LaVoie Group 978-745-4200 x106

Back to news